
|Videos|August 25, 2017
Dr. Tolaney Discusses Neratinib in HER2+ Breast Cancer
Author(s)Sara M. Tolaney, MD, MPH
Sara M. Tolaney, MD, MPH, instructor of medicine, Harvard Medical School, attending physician of medical oncology, Dana-Farber Cancer Institute, discusses neratinib (Nerlynx) in HER2-positive breast cancer.
Advertisement
Although trastuzumab (Herceptin) remains the standard of care, the recent approval of neratinib could shake up treatment decisions for certain subgroups of breast cancer.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression
2
HPV Vaccination and Evolving Screening Strategies Continue to Shape Cervical Cancer Prevention Efforts
3
The OncFive: Top Oncology Articles for the Week of 1/25
4
FDA Approval Sought for Lirafugratinib in Second-Line, FGFR2-Altered Cholangiocarcinoma
5



































